Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GCK | P35557 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | BCR | P11274 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CCR6 | P51684 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3596669 | 0.89 | HSD11B1 (0.76) | HSD11B1KMT2AGCKNAMPTL3MBTL1 | |
| SCHEMBL3616478 | 0.85 | HSD11B1 (0.70) | HSD11B1KMT2AGCKNAMPTL3MBTL1 | |
| SCHEMBL3610749 | 0.83 | HSD11B1 (0.68) | HSD11B1GCKNAMPTL3MBTL1GAA | |
| SCHEMBL3603381 | 0.82 | MAPT (0.75) | HSD11B1KMT2AGCKNAMPTGAA | |
| SCHEMBL2967364 | 0.79 | HSD11B1 (0.65) | HSD11B1KMT2AGCKPOLBMAPT | |
| SCHEMBL1872592 | 0.77 | F13A1 (0.72) | HSD11B1KMT2AGCKNAMPTMAPT | |
| SCHEMBL3615504 | 0.77 | MAPT (0.65) | HSD11B1KMT2AGCKNAMPTGAA | |
| SCHEMBL3610755 | 0.76 | HSD11B1 (0.58) | HSD11B1KMT2AGCKNAMPTL3MBTL1 | |
| SCHEMBL5772894 | 0.75 | HSD11B1 (0.62) | HSD11B1KMT2AGCKNAMPTGAA | |
| SCHEMBL6397625 | 0.73 | HSD11B1 (0.57) | HSD11B1KMT2AGCKNAMPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1968962-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-09-17 | — | — | EP | claimed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | claimed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-7825122-B2 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1968962-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | Amgen Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | AMGEN INC. | 2007-07-26 | — | — | US | disclosed |
| WO-2007070506-A2 | DIAZA HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173494-A1 | Diaza heterocyclic sulfonamide derivatives and their uses | GLP1R, GPR119, INSR | HSD11B1 685/4885KMT2A 821/4885GCK 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.